- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00447187
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was intended for surgical episcleral placement in the eye.
The study was a Phase 2/3, multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study of LX201 for prevention of corneal allograft rejection or graft failure following penetrating keratoplasty with LX201 implantation. Subjects were to be followed in an outpatient setting for safety and efficacy at 4-6 week intervals for 52 weeks following transplantation surgery.
After Visit 12 (Week 52), subjects in the USA and India with the implant in the study eye were to be followed for safety at least once per year for a 2-year period or until time of implant removal. For subjects in the USA and India, if the implant was removed at any time prior to the 3 year safety follow-up, the subject was to have a final safety follow up visit at 3 months post removal. In Germany, the implant was to be removed at Week 52 with a 3-month safety follow-up period after removal.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Erlangen, Germania, 91054
- Augenklinik, Universitat Erlangen-Nurnberg
-
Essen, Germania, 45122
- Cornea Bank, Universitätsklinikum Essen
-
Kiel, Germania, 24105
- Klinik fuer Ophthalmologie Campus Kiel
-
Muenchen, Germania, 80336
- Ludwig Maximilians Universität
-
München, Germania, 81675
- Augenklinik der Technischen Universität München
-
Wuerzburg, Germania, 97080
- Augenklinik Wuerzburg
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85032
- Cornea Consultants of Arizona
-
-
California
-
Loma Linda, California, Stati Uniti, 92354
- Loma Linda University Health Care
-
Los Angeles, California, Stati Uniti, 90033
- USC Doheny Eye Institute
-
-
Florida
-
Miami, Florida, Stati Uniti, 33136
- Bascom Palmer Eye Institute
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory Eye Center
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois at Chicago
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46260
- Price Vision Group
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21218
- The Eye Center at Union Memorial Hospital
-
Baltimore, Maryland, Stati Uniti, 21287
- Wilmer Eye Institute, Cornea Service
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- New England Eye Center
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48105
- W.K. Kellogg Eye Center - University of Michigan
-
-
Minnesota
-
Bloomington, Minnesota, Stati Uniti, 55431
- MN Eye Consultants, P.A.
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Tauber Eye Center
-
St. Louis, Missouri, Stati Uniti, 63141
- Ophthalmology Associates
-
-
New Jersey
-
Newark, New Jersey, Stati Uniti, 07103
- UMDNJ - New Jersey Medical School Institute of Ophthalmology and Visual Science
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Mount Sinai School of Medicine
-
New York, New York, Stati Uniti, 10003
- New York Eye and Ear Infirmary
-
Rockville Center, New York, Stati Uniti, 11570
- Ophthalmic Consultants of Long Island
-
Slingerlands, New York, Stati Uniti, 12159
- Cornea Consultants of Albany
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27705
- Duke University Eye Center
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- University Hospitals Case Medical Center
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75231
- Cornea Associates of Texas
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti, 23502
- Virginia Eye Consultants
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Eye Associates NW
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Subjects are candidates for a corneal transplant and are at increased immunological risk for graft failure, as evidenced by one or more of the following:
- ≥ 1 quadrant deep corneal vascularization
- verifiable history of graft failure due to rejection
- position of graft is < 1 mm from the limbus
Exclusion Criteria:
- Any condition that would greatly increase the risk of non-rejection graft failure such as Stevens-Johnson syndrome, xerophthalmia or severe exposure keratitis.
- Schirmer's test ≤ 5 mm in 1 minute
- Clinical evidence of limbal stem cell deficiency
- History of or active herpes simplex virus keratitis or other acute corneal infection
- Subjects who have had > 3 failed grafts in the study eye
- Uncontrolled glaucoma as evidenced by an intraocular pressure of >21 mmHg while on maximal medical therapy
- Clinically suspected or confirmed ocular lymphoma
- Treatment with a systemic immunosuppressive regimen within the previous 30 days; systemic prednisone (or its equivalent) of ≤ 10 mg daily is, however, permitted.
- Any implantable corticosteroid-eluting device (e.g., Retisert™, Posurdex®, Medidur™, I-vation™ TA intravitreal implant)
- Subjects who periodically require high-dose systemic steroid treatment (e.g., for exacerbation of chronic obstructive pulmonary disease).
- Subjects who have received treatment with a monoclonal antibody or any other biologic therapy within the previous 90 days or alemtuzumab within the previous 12 months
- History of herpes zoster or varicella infection within 6 weeks prior to enrollment, or chicken pox exposure within 21 days before enrollment
- Seropositivity for human immunodeficiency virus (HIV)
- Previous exposure or known contraindication to administration of cyclosporine
- Recipients of a solid organ transplant
- Currently pregnant or lactating
- Active, extraocular and/or systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of active hepatitis A, B or C
- Severe anemia (hemoglobin < 6 g/dL), leukopenia (white blood cell count [WBC] < 2500 mm3), thrombocytopenia (platelet count < 80,000 mm3), polycythemia (hematocrit [Hct] > 54% [male] or Hct > 49% [female]) or clinically significant coagulopathy
- Current malignancy or a history of malignancy (within the previous 5 years) except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix that has been treated successfully
- Active peptic ulcer disease
- Co-morbid conditions that require immunosuppression
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: LX201 Impianto da 0,50 pollici
L'impianto LX201 conteneva il 30% di ciclosporina A in peso e 0,50 pollici di lunghezza
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Sperimentale: Impianto LX201 da 0,75 pollici
L'impianto LX201 conteneva il 30% di ciclosporina A in peso e 0,75 pollici in lunghezza
|
LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight. LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded. |
Comparatore placebo: Impianto Placebo da 0,75 pollici
Impianto di silicone non contenente ciclosporina A, 0,75 pollici di lunghezza
|
Il placebo era un impianto di silicone lungo 0,75 pollici.
Non conteneva ciclosporina A
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
graft rejection or graft failure
Lasso di tempo: 52 weeks
|
52 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: Eddy Anglade, MD, Chief Medical Officer, Lux Biosciences, Inc.
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- LX201-01
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su LX201
-
Lux Biosciences, Inc.TerminatoTrapianto di cornea | Rigetto dell'innesto cornealeStati Uniti, Germania